LZ
Lonza Group AG
LZAGF · OTC
$701.63 +2.40% (+$16.42)
1M +3.68%
Market Cap CHF 39.8B
P/E Ratio 41.94x
Div. Yield 0.47%
ROE 10.78%
Bulios Fair Price
$392.22
44.1% downside
Current Price
$701.63
Undervalued Fair Value Overvalued
According to Bulios Fair Price, LZAGF is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Analysis
An AI report on the business, its finances, valuation, sentiment, news and risks - written in a few minutes.
Piotroski F-Score Strong
7/9Valuation
22 /100
Expensive P/S 6.09x
P/E 41.94x
P/B 4.36x
Growth
14 /100
Declining Book val. growth 4.83%
EPS growth 6.14%
Rev. growth 1.62%
Profitability
54 /100
Moderate Op. margin 18.97%
Gross margin 35.35%
FCF margin 3.32%
Quality
40 /100
Average ROA 5.00%
ROIC 6.51%
Asset turnover 0.34x
Debt
73 /100
Low Int. coverage 7.80x
Debt/Equity 0.46x
Net debt/EBITDA 2.65x
Stability
82 /100
Stable EPS volatility 48.58%
Beta 0.84x
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about LZAGF
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Wolfgang Wienand
Employees
17,995
Headquarters
Basel